Form 8-K - Current report:
SEC Accession No. 0001493152-24-043066
Filing Date
2024-10-30
Accepted
2024-10-30 16:30:27
Documents
14
Period of Report
2024-10-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 60680
2 ex10-1.htm EX-10.1 178118
  Complete submission text file 0001493152-24-043066.txt   453811

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE zvsa-20241029.xsd EX-101.SCH 3012
4 XBRL LABEL FILE zvsa-20241029_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE zvsa-20241029_pre.xml EX-101.PRE 24163
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3815
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 241410793
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)